Last reviewed · How we verify

NCT05481788: EOPMV

External Evaluation of Vancomycin Population Pharmacokinetic Models

Completed Last updated 1 August 2022
What this trial tests

trial in Vancomycin Dosage in 300 participants. Completed in 1 November 2021.

Timeline
16 April 2021
Primary endpoint
1 October 2021
1 November 2021

Quick facts

Lead sponsorUniversity Hospital, Brest
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date16 April 2021
Primary completion1 October 2021
Estimated completion1 November 2021
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Brest

Who can join

18 and older, any sex, with Vancomycin Dosage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

All patients treated with vancomycin hospitalized outside of ICU in Brest University Hospital from 1rst january 2019 to 1rst january 2021 will be screened for inclusion. Vancomycin dosage, age, weight and serum creatinin will be recorded. Seven pharmacokinetic models' predictive performance will be evaluated on this database. Using the best model, we will perform Monte-Carlo simulation to elaborate dosing nomograms and develop dosing recommandations of continuous infusion of vancomycin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Brest trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05481788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing